Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 4/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590909 | 0.70 | NPSR1 (1.00) | NPSR1KDM4EALDH1A1 | |
| SCHEMBL31210085 | 0.66 | POLB (0.61) | NPSR1KDM4EALDH1A1HPGD | |
| SCHEMBL10879830 | 0.66 | POLB (0.61) | NPSR1KDM4EALDH1A1HPGD | |
| SCHEMBL28460971 | 0.66 | KDM4E (0.46) | RENKDM4EALDH1A1HPGDHTR7 | |
| SCHEMBL2595693 | 0.64 | NPSR1 (1.00) | NPSR1KDM4EALDH1A1HPGD | |
| SCHEMBL2587268 | 0.63 | NPSR1 (0.63) | NPSR1KDM4EALDH1A1PLA2G2A | |
| SCHEMBL2593998 | 0.63 | NPSR1 (0.63) | NPSR1ALDH1A1 | |
| SCHEMBL31590097 | 0.62 | P2RX4 (0.56) | NPSR1KDM4EALDH1A1HPGD | |
| SCHEMBL2586743 | 0.60 | NPSR1 (0.58) | NPSR1KDM4EALDH1A1PLA2G2A | |
| Diphenylmethane SCHEMBL8743340 | 0.60 | PLA2G10 (0.71) | PLA2G10PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137220-A1 | SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |